Oncospire Genomics

Share on: 

Launched in 2013, Oncospire was established as an equally owned joint venture between Cancer Genetics, Inc. and Mayo Clinic. Focussed on developing and commercializing next generation sequencing (NGS) panels for areas of critical unmet need in Oncology, Oncospire Genomics is currently developing targeted NGS diagnostic panels for solid tumors and hematological cancers, including lung cancer, multiple myeloma, and follicular lymphoma.

Rochester MN
United States